^
    Back
    Association details:
    Biomarker:SRF overexpression
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Cancers (Basel)
    Title:

    Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer

    Published date:
    11/27/2020
    Excerpt:
    ...we assessed SRF immunoreactivity in metastatic tissues from CRPC patients…23 patients who were treated with enzalutamide showed that high SRF expression levels were associated with shorter survival time on enzalutamide, for both bone and visceral metastases (Figure 5B,C). These data indicate that SRF expression is associated with the enzalutamide response, with higher levels of SRF protein expression associated with resistance to treatment.
    DOI:
    10.3390/cancers12123540
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    AACR-NCI-EORTC 2020
    Title:

    Inhibition of serum response factor as a new strategy to overcome resistance to enzalutamide in prostate cancer

    Published date:
    10/09/2020
    Excerpt:
    Next, SRF expression was assessed in a TMA of CRPC metastases to study the relationship between SRF expression and response to Enzalutamide in patients. Here we showed that SRF expression is elevated in Enzalutamide-resistant patients…